With 4.69 million shares changed hands, the volume of the stock remained heavier than its average volume of 2.37 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $5.95 whereas the lowest price it dropped to was $5.17. The 52-week range on VNDA shows that it touched its highest point at $6.98 and its lowest point at $3.30 during that stretch. It currently has a 1-year price target of $5.21. Beta for the stock currently stands at 0.70.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of VNDA was up-trending over the past week, with a rise of 15.13%, but this was up by 21.51% over a month. Three-month performance surged to 46.92% while six-month performance rose 21.24%. The stock lost -21.15% in the past year, while it has gained 29.86% so far this year. A look at the trailing 12-month EPS for VNDA yields 0.04 with Next year EPS estimates of -0.33. EPS is expected to grow by 36.10% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -37.98%.
Float and Shares Shorts:
At present, 57.53 million VNDA shares are outstanding with a float of 55.13 million shares on hand for trading. On 2024-04-15, short shares totaled 2.07 million, which was 359.99999999999994 higher than short shares on 1710460800. In addition to Dr. Mihael H. Polymeropoulos M.D. as the firm’s Founder, President, CEO & Chairman of The Board, Mr. Kevin Patrick Moran serves as its Senior VP, CFO & Treasurer.
Institutional Ownership:
Through their ownership of 0.88391 of VNDA’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2023-12-31, VNDA reported revenue of $45271000.0 and operating income of -$7094000.0. The EBITDA in the recently reported quarter was -$5936000.0 and diluted EPS was -$0.04.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for VNDA since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential.
